Overview

A Healthy Volunteer Study to Evaluate Reversibility of Induced Impairment of Cognition

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if cognitive impairment induced by scopolamine is reversed using donepezil and/or AZD1446 as compared to placebo, as assessed by electroencephalogram (EEG) measures.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Donepezil